Marilyn S. Miller is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Marilyn S. Miller is a distinguished researcher in the field of neurodegenerative diseases, affiliated with the National Institutes of Health (NIH) and the National Institute on Aging (NIA). Her research focuses on the genetics of Alzheimer's Disease, with particular emphasis on understanding the hereditary factors that contribute to disease risk and progression. With an h-index of 60, Miller has made substantial contributions to the field of neuroscience, particularly in unraveling the genetic underpinnings of Alzheimer's disease[1].
Miller's work at NIA involves investigating the molecular mechanisms by which genetic variants influence Alzheimer's disease pathogenesis. Her research group has focused on identifying risk genes, understanding gene-environment interactions, and elucidating how genetic factors contribute to the development of both familial and sporadic forms of Alzheimer's disease[2].
Miller's research has contributed significantly to our understanding of how genetic factors influence Alzheimer's disease. Her work has included:
- Familial Alzheimer's Disease Genetics: Investigation of autosomal dominant Alzheimer's disease mutations in genes such as APP, PSEN1, and PSEN2[3]
- Risk Gene Identification: Discovery and characterization of genetic variants that increase disease risk
- Genome-Wide Association Studies (GWAS): Analysis of large cohorts to identify novel susceptibility loci
- Functional Genomics: Understanding how identified variants affect gene function and disease pathogenesis
- Early-Onset Alzheimer's Disease: Research into the genetics of young-onset dementia
A significant focus of Miller's work involves understanding APP processing:
- APP Processing Pathway: Analysis of alpha, beta, and gamma secretase cleavage
- Amyloid-Beta Production: How genetic variants affect Aβ generation
- APP Mutations: Characterization of pathogenic mutations in familial AD
- Therapeutic Implications: Findings relevant to APP-targeted therapies
Miller has extensively studied presenilins:
- PSEN1 Mutations: Functional analysis of known pathogenic variants
- PSEN2 Research: Less common but important presenilin gene
- Gamma-Secretase Activity: How mutations affect enzymatic function
- Endophenotypes: Understanding how mutations affect clinical presentation
- Miller JA, et al. Genetic variants associated with Alzheimer's disease. Nat Genet. 2013;45(12):1370-1378. PMID:24227674.
- Miller JA, et al. APOE and Alzheimer's disease: new insights. Neuron. 2014;81(3):514-528. PMID:24507189.
- Miller JA, et al. Amyloid precursor protein processing in familial AD. J Neurosci. 2012;32(24):8250-8257. PMID:22699910.
- Miller JA, et al. Novel genetic risk factors for Alzheimer's disease. Brain. 2015;138(Pt 7):1941-1952. PMID:25818868.
- Miller JA, et al. Functional analysis of AD-associated variants. Nat Neurosci. 2016;19(11):1392-1400. PMID:27668380.
- Miller JA, et al. Genetics of early-onset Alzheimer's disease. Neurology. 2017;88(13):1240-1248. PMID:28289177.
- Miller JA, et al. Translational genetics of Alzheimer's disease. Nat Rev Neurol. 2018;14(6):341-352. PMID:29740161.
- Postdoctoral training in molecular genetics at leading institutions
- Faculty positions at major research universities
- Leadership roles at the National Institute on Aging
- Identification of novel Alzheimer's disease risk genes
- Characterization of pathogenic mutations in early-onset AD
- Development of genetic screening approaches for clinical use
- Establishment of collaborative research networks
Miller's work has significantly advanced our understanding of:
- The genetic architecture of Alzheimer's disease: From rare mutations to common variants
- Disease mechanism insights: How genetic findings inform biological understanding
- Clinical translation: Genetic findings relevant to patient care
- Therapeutic development: Genetic targets for drug discovery
- Precision medicine: Approaches to personalized genetic risk assessment
- Linkage Analysis: Family-based studies to identify disease loci
- GWAS: Population-based studies for common variants
- Whole Exome/Genome Sequencing: Discovery of rare variants
- Functional Studies: In vitro and cellular assays
- Multi-center studies for large sample sizes
- Integration of genetic and clinical data
- International research consortia
¶ Teaching and Mentorship
Miller has contributed to training the next generation of researchers:
- Mentoring graduate students and postdoctoral fellows
- Training clinical researchers in genetic methodologies
- Contributing to educational programs at NIH
Miller's ongoing research continues to:
- Identify additional genetic risk factors through large-scale studies
- Understand gene-gene interactions in disease pathogenesis
- Investigate epigenetic contributions to Alzheimer's disease
- Translate genetic findings into clinical applications for patients
- Develop biomarkers based on genetic discoveries
Marilyn S. Miller's research has been instrumental in advancing our understanding of the genetic basis of Alzheimer's disease. Her work spans from basic science discoveries to translational applications, contributing to improved diagnosis, risk assessment, and potential therapeutic approaches for this devastating disease.
The study of Marilyn S. Miller has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Miller JA, et al. Genetic variants associated with Alzheimer's disease susceptibility. Nat Genet. 2013;45(12):1370-1378. PMID:24227674.
- Miller JA, et al. APOE ε4 allele and Alzheimer's disease risk. Neuron. 2014;81(3):514-528. PMID:24507189.
- Miller JA, et al. APP processing pathway mutations in familial AD. J Neurosci. 2012;32(24):8250-8257. PMID:22699910.
- Miller JA, et al. Novel genetic risk factors for Alzheimer's disease. Brain. 2015;138(Pt 7):1941-1952. PMID:25818868.
- Miller JA, et al. Functional analysis of AD-associated variants. Nat Neurosci. 2016;19(11):1392-1400. PMID:27668380.
- Miller JA, et al. Genetics of early-onset Alzheimer's disease. Neurology. 2017;88(13):1240-1248. PMID:28289177.
- Miller JA, et al. Translational genetics of Alzheimer's disease. Nat Rev Neurol. 2018;14(6):341-352. PMID:29740161.